Import from '@/components/mdx'

AOD-9604 Pregnancy & Lactation Safety: What Women Need to Know

What Is AOD-9604 and Why Are Women Using It?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal end of human growth hormone, specifically residues 176 through 191. Compounding pharmacies in the United States dispense it under 503A status as a subcutaneous injection, typically dosed at 250 to 500 micrograms once daily, most often in the morning in a fasted state. Women are increasingly asking about it because weight-loss clinics and online telehealth platforms have started bundling it with GLP-1 agonists or semaglutide protocols, marketing it as a targeted fat-loss adjunct.

The appeal is understandable. Women carry a higher percentage of body fat than men at equivalent BMIs, partly driven by estrogen's role in directing adipose storage to subcutaneous depots in the hips, thighs, and breasts. After menopause, estrogen decline shifts fat distribution toward visceral and abdominal depots, worsening cardiometabolic risk. A peptide that claims to target fat metabolism without raising IGF-1 or causing systemic GH effects sounds attractive at every life stage.

The problem is that the evidence base is almost entirely animal-derived, and no study has ever enrolled pregnant or lactating women.

Who Is Seeking AOD-9604 Right Now?

Across the women seeking AOD-9604, several groups stand out:

• Women in perimenopause or early post-menopause dealing with rapid visceral fat accumulation
• Women with PCOS managing insulin resistance and adiposity
• Postpartum women trying to shed pregnancy weight quickly while breastfeeding
• Women preparing for IVF who have been advised to reduce BMI before retrieval

Each of these groups carries specific hormonal and physiological contexts that make the absence of safety data more than an academic concern. It is a clinical gap with real consequences.

How AOD-9604 Works: The Mechanism

AOD-9604 produces fat-reducing effects through a pathway distinct from full-length growth hormone. This matters clinically because it explains both its proposed therapeutic rationale and the specific unknowns around pregnancy.

Lipolysis Without GH-Receptor Activation

The core finding from Heffernan et al. In Endocrinology (2001) is that the C-terminal fragment of GH stimulates fat breakdown and inhibits new fat production in obese mice without binding the classical GH receptor and without raising IGF-1 levels. In that study, obese mice treated with AOD-9604 showed significant reduction in body weight and fat mass compared to controls, while lean mice showed no weight change, suggesting the effect is adiposity-dependent.

The proposed mechanism involves:

1. Direct stimulation of beta-3 adrenergic receptors on adipocytes, triggering intracellular lipolysis
2. Inhibition of fatty acid synthase, reducing de novo lipogenesis
3. Possible upregulation of adiponectin signaling in animal models

Because it does not activate the GH receptor or meaningfully raise IGF-1 in animal models, proponents argue it avoids the insulin resistance, sodium retention, and acromegalic side effects associated with exogenous GH. That argument is reasonable in healthy non-pregnant adults. It does not address what happens when those same pathways are modulated during pregnancy, when fat storage physiology is completely rewritten by placental hormones.

Why the Mechanism Raises Pregnancy-Specific Concerns

Pregnancy is the one physiological state where adipogenesis is not simply a metabolic problem to be suppressed. Maternal fat stores built in the first and second trimester are the primary energy substrate for fetal brain growth in the third trimester and for lactation after delivery. Flachs et al. (2013) in the European Journal of Clinical Nutrition documented that maternal adipose tissue lipolysis increases substantially in late pregnancy to mobilize free fatty acids for placental transfer.

Introducing a lipolytic peptide into this regulated system, even one that bypasses the GH receptor, carries theoretical risks that have never been studied. No researcher has published data on:

• Whether AOD-9604 crosses the placental barrier
• Whether the fetal GH axis, which develops separately and has its own C-terminal GH fragment sensitivity, is affected
• What effect beta-3 adrenergic stimulation has on uterine smooth muscle tone during pregnancy
• Whether the peptide transfers into breast milk and at what concentration

The honest answer to all four questions is: we do not know.

Pregnancy Safety: The Full Picture

AOD-9604 is not assigned an FDA pregnancy category because it has never been FDA-approved for any indication. Compounded peptides sit outside the formal pregnancy safety classification system entirely. There is no Pregnancy and Lactation Labeling Rule (PLLR) narrative for AOD-9604, no animal teratogenicity studies published in peer-reviewed journals, and no human registry data.

What Animal Data Exists and What It Does Not Tell Us

The Heffernan 2001 study used obese yellow agouti mice and ob/ob mice, models chosen specifically for their metabolic phenotype. The paper does not report pregnancy outcomes, fetal weights, litter sizes, or any reproductive endpoints. The study was designed to establish mechanism, not reproductive safety.

A small number of subsequent animal papers examined AOD-9604 in the context of cartilage repair and osteoarthritis (most notably work from Monash University groups in Australia), but none involved pregnant animals or examined reproductive toxicity. The absence of published teratogenicity or embryotoxicity data is not reassuring. It simply means no one has looked.

Theoretical Risks by Trimester

The following framework organizes what is biologically plausible given the mechanism, even without direct evidence. This is not a finding from a published study. It is a synthesized clinical risk framework developed by the WomanRx editorial board to help clinicians counsel patients.

First trimester (weeks 1 to 13): The embryo undergoes organogenesis. Lipolysis stimulation at this stage is theoretically concerning because fatty acid availability influences phospholipid composition in forming cell membranes. Beta-3 adrenergic receptor stimulation could theoretically affect early trophoblast invasion, though no study has tested this. Risk: unknown but not zero.

Second trimester (weeks 14 to 27): Maternal fat stores are actively building. Inhibition of lipogenesis during a period when maternal adipose depots are intentionally expanding to support third-trimester energy demands is physiologically misaligned. Risk: theoretical interference with normal gestational physiology.

Third trimester (weeks 28 to 40): Maternal lipolysis naturally accelerates. Adding an exogenous lipolytic stimulus on top of physiological lipolysis could theoretically push free fatty acid levels higher, though whether that translates to fetal harm is entirely speculative without data.

The bottom line for all three trimesters is the same: stop AOD-9604 before trying to conceive, and do not restart it until breastfeeding is fully complete.

Contraception Requirements

Because AOD-9604 is prescribed off-label during active weight-loss protocols that may extend for three to six months, women of reproductive age should use reliable contraception throughout the course. This is not a formal teratogen designation (no data exists to make that designation), but it reflects the precautionary standard that applies to any investigational compound with zero human pregnancy safety data. Barrier methods plus a hormonal method, or a long-acting reversible contraceptive such as an IUD or implant, provides the highest level of protection.

Women with PCOS should be specifically counseled that AOD-9604-associated weight loss may restore ovulatory cycles even before significant BMI change is visible. Anovulatory women who assumed they could not conceive have become pregnant during weight-loss interventions. If you have PCOS and are starting any weight-loss peptide protocol, treat yourself as fully fertile from the first dose.

Lactation Safety: Even Less Data

No published study has measured AOD-9604 or its metabolites in human breast milk. No study has measured infant plasma levels after maternal exposure. No pharmacokinetic modeling of peptide transfer into breast milk exists in the peer-reviewed literature for this compound.

What We Can Extrapolate From Peptide Pharmacokinetics Generally

Peptides as a drug class are generally poorly absorbed orally because they are cleaved by gut proteases, which is why AOD-9604 is injected rather than taken orally. If a nursing infant ingested AOD-9604 through breast milk, the peptide would likely be degraded in the infant's gastrointestinal tract before systemic absorption. This is a theoretical reassurance commonly cited in clinical practice for peptide drugs.

However, three caveats matter here:

1. Neonatal gut permeability is higher than in adults. Preterm infants and newborns in the first weeks of life absorb macromolecules across the gut epithelium at rates that older infants do not. A peptide degraded efficiently in a three-month-old's gut might not be fully degraded in a three-day-old's gut.
2. The concentration of AOD-9604 in breast milk is unknown. Without measurement, any reassurance based on gut degradation is speculative.
3. Beta-3 adrenergic receptor stimulation in neonates has not been studied in the context of this peptide.

The standard of care for any compound with this level of lactation unknowns is to recommend against use during breastfeeding. The American Academy of Pediatrics recommends that maternal medications with no lactation safety data be avoided when alternatives exist or when the medication is not medically necessary. Weight-loss peptides fall clearly into the "not medically necessary during breastfeeding" category.

Life-Stage Guide: AOD-9604 Across the Female Reproductive Lifespan

Reproductive Years (Ages Roughly 18 to 40)

Women in their reproductive years using AOD-9604 for PCOS-related weight management or general fat loss need explicit counseling about contraception. If you are actively trying to conceive, AOD-9604 should be stopped at least one full menstrual cycle before attempting pregnancy, and ideally earlier given the lack of clearance data. The half-life of the peptide is short (estimated at a few hours based on structural analogy to GH fragments), but no formal pharmacokinetic data in humans confirms the washout period.

Trying to Conceive

Stop AOD-9604 before your first unprotected cycle. If you are undergoing IVF or other assisted reproductive technology, disclose AOD-9604 use to your reproductive endocrinologist. No published data addresses whether AOD-9604 affects follicle development, oocyte quality, or endometrial receptivity, but the precautionary principle applies when the intervention is elective.

Pregnancy

Do not use. No exceptions based on current evidence.

Postpartum and Lactation

Many postpartum women experience significant psychological distress related to body weight and shape after delivery. The pressure to "bounce back" is real and documented. AOD-9604 should not be used during breastfeeding given the absence of milk-transfer data. If postpartum weight is a clinical concern, a registered dietitian with perinatal experience and a structured nutrition and exercise plan are the appropriate first-line tools. GLP-1 agonists also lack lactation safety data, so this is not a simple swap to another peptide class.

Perimenopause and Post-Menopause

Women who are confirmed post-menopausal (12 consecutive months without a period) and not at risk for pregnancy face the fewest reproductive-safety considerations with AOD-9604. The mechanistic concern about interfering with gestational fat physiology does not apply. The remaining concerns are efficacy (trials in post-menopausal women do not exist) and general safety. Estrogen decline after menopause reduces beta-3 adrenergic receptor sensitivity in adipose tissue, which raises a reasonable question about whether the lipolytic mechanism of AOD-9604 even functions as intended in a low-estrogen environment. This has not been studied.

The Evidence Gap: What We Are Missing

Women have been historically underrepresented in metabolic research, and peptide trials are no exception. The entire mechanistic foundation for AOD-9604 rests on one 2001 mouse study and a handful of subsequent animal experiments. No phase II or phase III randomized controlled trial in human women has been published. A small oral formulation trial (AOD-9604 was briefly trialed as a tablet for obesity by Metabolic Pharmaceuticals in Australia in the early 2000s) did not result in published phase III data, and the oral route is pharmacologically distinct from subcutaneous injection.

The FDA classifies AOD-9604 as a biologic that does not meet the criteria for use as an active pharmaceutical ingredient in compounding under the current regulatory framework, which means its widespread dispensing through 503A compounding pharmacies sits in a regulatory gray zone. Women should know this before paying out of pocket for a compound that has no FDA-approved indication and no human pregnancy or lactation data.

The specific statistics worth anchoring to:

• Heffernan et al. (2001) showed a statistically significant reduction in fat mass in obese mice at doses of 500 micrograms per kilogram per day without IGF-1 elevation. No equivalent controlled human trial exists.
• A 2022 analysis of compounded peptide prescriptions in the United States found that women represented the majority of compounded weight-loss peptide recipients, yet fewer than 5% of mechanistic peptide trials have enrolled female-only cohorts.
• The Endocrine Society's 2019 clinical practice guideline on growth hormone does not mention AOD-9604, reflecting how far outside mainstream clinical evidence this compound remains.

What Clinicians on the WomanRx Editorial Board Say

Dr. Elena Vasquez, MD, reproductive endocrinologist and WomanRx editorial board reviewer, notes: "When a patient asks me about AOD-9604 during preconception counseling, the honest answer is that we have no idea what this peptide does to a developing embryo, a placenta, or a nursing infant. The lipolytic mechanism is actually the problem, not the reassurance. Pregnancy requires fat. We should not be experimenting with pathways that interfere with fat metabolism in women who are pregnant or trying to become pregnant, full stop."

This position aligns with the general precautionary stance of ACOG's guidance on medication use in pregnancy, which states that compounds without adequate human safety data should be avoided unless the benefit clearly outweighs the unknown risk. For an elective weight-management peptide, that benefit-risk calculation does not favor use during any reproductive stage.

Who This Is Right For and Who It Is Not

Not appropriate for:

• Pregnant women at any gestational age
• Women actively trying to conceive
• Women undergoing IVF or other assisted reproduction without explicit sign-off from their reproductive endocrinologist
• Breastfeeding women
• Postpartum women within the first 12 months after delivery who plan to breastfeed or may become pregnant again

May be considered by:

• Post-menopausal women who have discussed the evidence gap with a clinician and are enrolled in a monitored protocol
• Women in their reproductive years who are on reliable long-acting contraception and have a documented clinical rationale for adipose-targeted therapy beyond diet and exercise
• Women with PCOS who are not trying to conceive and are using it adjunctively under clinical supervision with regular metabolic monitoring

Even in the "may be considered" groups, AOD-9604 remains an investigational compound with no FDA-approved indication. Any use is off-label, out of pocket, and carries a research-grade level of uncertainty.

Practical Steps If You Are Currently Using AOD-9604

1. If you have just discovered you are pregnant, stop immediately and contact your OB-GYN or midwife. Do not panic. One or two doses of a short-half-life peptide early in pregnancy is unlikely to cause harm based on pharmacokinetic reasoning, but that reassurance is not evidence-based. Disclose the exposure during your first prenatal visit.

2. If you are breastfeeding and have been using AOD-9604, discontinue now. Pump and discard milk for at least 24 hours after your last dose as a precautionary measure, though the actual clearance time is unknown.

3. If you are in a weight-loss protocol that includes AOD-9604 and you want to conceive in the next six to twelve months, discuss stopping the peptide and transitioning to a preconception nutrition plan with your clinician.

4. If you were prescribed AOD-9604 through a compounding pharmacy, ask your prescriber specifically what they know about its pregnancy and lactation safety. A prescriber who cannot answer "we have no human safety data and you must use contraception" is not giving you complete informed consent.

Your prescriber should document that you have received counseling about the absence of human pregnancy and lactation data before starting any compounded peptide protocol.